Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
- Revenue in EUR (TTM)1.76bn
- Net income in EUR-38.15m
- Incorporated2008
- Employees1.15k
- Locationargenx SELaarderhoogtweg 25AMSTERDAM 1101 EBNetherlandsNLD
- Phone+31 763030
- Websitehttps://www.argenx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zealand Pharma A/S | 10.30m | -141.10m | 7.77bn | 298.00 | -- | 6.49 | -- | 753.94 | -16.69 | -16.69 | 1.21 | 125.74 | 0.013 | 3.73 | 0.2625 | 303,834.00 | -17.83 | -42.74 | -18.63 | -50.24 | 72.06 | 96.13 | -1,369.25 | -464.66 | 35.49 | -- | 0.042 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| Qiagen NV | 1.86bn | 87.98m | 9.04bn | 5.90k | 104.68 | 2.69 | 31.58 | 4.85 | 0.3863 | 0.3863 | 8.33 | 15.04 | 0.3229 | 2.03 | 5.71 | 311,945.20 | 1.53 | 5.41 | 1.77 | 6.53 | 62.73 | 64.65 | 4.73 | 16.35 | 1.89 | -- | 0.3523 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Genmab A/S | 2.65bn | 621.89m | 13.76bn | 2.64k | 21.74 | 3.09 | 34.55 | 5.20 | 71.38 | 71.38 | 303.48 | 502.60 | 0.5277 | 10.98 | 3.37 | 8,966,878.00 | 12.39 | 17.43 | 13.76 | 18.59 | 96.08 | -- | 23.47 | 35.87 | 5.15 | -- | 0.03 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
| argenx SE | 1.76bn | -38.15m | 34.25bn | 1.15k | -- | -- | -- | 19.47 | -0.7951 | -0.7951 | 28.94 | -- | -- | -- | -- | 1,532,787.00 | -- | -17.65 | -- | -19.79 | 89.56 | -- | -2.17 | -97.72 | -- | -- | -- | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
| Lonza Group AG | 7.15bn | 612.16m | 43.06bn | 17.83k | 70.31 | 4.17 | 35.41 | 6.02 | 7.94 | 7.94 | 92.53 | 133.83 | 0.3767 | 2.60 | 4.35 | 372,000.00 | 3.23 | 5.07 | 3.81 | 6.21 | 29.21 | 39.15 | 8.57 | 14.52 | 1.38 | 5.14 | 0.2873 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 20 May 2024 | 2.95m | 4.94% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 2.05m | 3.43% |
| Schroder Investment Management Ltd.as of 31 Aug 2024 | 1.95m | 3.27% |
| Wellington Management Co. LLPas of 24 Jun 2024 | 1.82m | 3.04% |
| Norges Bank Investment Managementas of 27 Sep 2024 | 1.62m | 2.71% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 1.19m | 1.98% |
| Federated Global Investment Management Corp.as of 30 Sep 2024 | 829.98k | 1.39% |
| Bellevue Asset Management AGas of 30 Jun 2024 | 688.00k | 1.15% |
| Geode Capital Management LLCas of 07 Nov 2024 | 580.15k | 0.97% |
| BlackRock Advisors (UK) Ltd.as of 03 Oct 2024 | 535.71k | 0.90% |
